March 31, 2021 - A settlement in principle had was filed by the parties.

February 18, 2021 - A third amended consolidated complaint was filed.

January 5, 2021 - The court granted the defendants' motion to dismiss. The plaintiffs were given leave to amend the complaint.

January 29, 2020 - A motion to dismiss the second amended consolidated complaint was filed.

December 20, 2019 - A second amended consolidated complaint was filed.

November 12, 2019 - The court granted the defendants' motion to dismiss. The plaintiffs were given leave to amend the complaint.

October 22, 2018 - A motion to dismiss the amended consolidated complaint was filed.

September 20, 2018 - An amended consolidated complaint was filed.

August 21, 2018 - The court granted the defendants' motion to dismiss. The plaintiffs were given leave to amend the complaint.

December 5, 2017 - A motion to dismiss the consolidated complaint was filed.

October 6, 2017 - A consolidated complaint was filed.

February 13, 2017 (Shareholders Foundation) - An investor in shares of Galena Biopharma Inc (NASDAQ:GALE) filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Galena Biopharma Inc in connection with certain allegedly false and misleading statements made between August 11, 2014 and January 31, 2017.

According to the complaint the plaintiff alleges on behalf of purchasers of Galena Biopharma Inc (NASDAQ:GALE) common shares between August 11, 2014 and January 31, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 11, 2014 and January 31, 2017 the Defendants made false and/or misleading statements and/or failed to disclose that Galena Biopharma Inc’s sales of Abstral were based on unsustainable sales and marketing practices, that such sales and marketing practices could subject Galena Biopharma Inc to a criminal investigation, and that as a result, Defendants’ statements about Galena’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Portland, Or based Galena Biopharma Inc is a biopharmaceutical company that focuses on developing and commercializing targeted oncology therapeutics that address unmet medical need. On November 9, 2015 Galena Biopharma Inc disclosed plans to “divest its commercial business,” which included the Company’s breakthrough cancer pain drug, Abstral.

On March 10, 2016, Galena Biopharma Inc disclosed that “[a] federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes,” and that the Company had received a trial subpoena for documents in connection with that investigation. Galena Biopharma Inc further disclosed that “other governmental agencies may be investigating our Abstral promotion practices,” and that “on December 16, 2015, we received a subpoena issued by the U.S. Attorney’s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral.”

On January 31, 2017, Galena Biopharma Inc announced the resignation of Mark W. Schwartz from his positions as President, Chief Executive Officer, and a member of the Board of Directors. Shares of Galena Biopharma Inc (NASDAQ:GALE) declined to as low as $0.0.81 per share on February 8, 2017.